$1.63
-0.19-10.44%
Last update: Nov 10, 4:00 PM
Cardlytics Inc
CDLXNASDAQ
Cardlytics fell 87.6% from $14.70 to $1.82, behind the S&P 500's +9.8%. Its worst day was May 8 (−18.1%), and its low came Oct 28 at $1.60.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Cardlytics closed at its highest level of the year, 3.4% above where the year started.
+6.3% · S&P 500 0.0%
EPS of $0.30 beat the $-1.50 estimate on $56.1M revenue (est. $54.5M); Q1 revenue guidance of $35.0M–$40.0M against the $48.7M consensus.
Story events cover the past 12 months · Times ET
−9.4% · S&P 500 −0.6%
Cardlytics shares rose 16.7%, while the S&P 500 rose 2.9%.
+16.7% · S&P 500 +2.9%
EPS of $-1.10 beat the $-2.40 estimate on $34.3M revenue (est. $37.1M); Q2 revenue guidance of $35.0M–$40.0M against the $38.7M consensus.
−18.1%, the year's worst day · S&P 500 +0.8%
Cardlytics shares rose 21.7%, while the S&P 500 rose 1.0%.
+21.7%, the year's best day · S&P 500 +1.0%
EPS of $-0.81 beat the $-1.35 estimate on $36.9M revenue (est. $37.0M); Q3 revenue guidance of $34.0M–$39.0M against the $38.6M consensus.
−13.9% · S&P 500 −0.2%
Cardlytics shares fell 14.5%, while the S&P 500 fell 0.4%.
−14.5% · S&P 500 −0.4%
Cardlytics closed at its lowest level of the year, 89.1% below where the year started.
−4.8% · S&P 500 +0.3%
EPS of $-1.03 beat the $-1.04 estimate on $32.9M revenue (est. $37.1M); Q4 revenue guidance of $35.0M–$39.0M against the $41.2M consensus.
−11.0% · S&P 500 +0.3%
Where it ended: a close of $1.82 on Nov 9, 2026. Up next: Q4 2026 earnings on Mar 3, 2027 (EPS est. $-1.15, revenue est. $35.5M).
Nothing in the past 12 months.
All CDLX dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CDLX and SPY from Benzinga historical bars. Not investment advice.
